Emerging Role of GLP-1 Agonists in Obesity

Introduction

Obesity is a chronic disease with a high prevalence and associated comorbidities, making it a growing global concern. GLP-1 agonists, used to treat type 2 diabetes, have been shown to be effective in promoting weight loss in preclinical and clinical studies. This review summarizes numerous studies conducted on the main drugs in the GLP-1 agonists class, outlining the maximum achievable weight loss.

Prevalence of Obesity Globally

Obesity is defined by a body mass index (BMI) of 30 kg/m2 or higher. The World Health Organization (WHO) reports that almost 60% of European adults are overweight or obese, with higher prevalence levels among men than women. Obesity is linked to increased mortality rates and is predicted to overtake smoking as the leading preventable risk factor for cancer in some countries.

Complications of Obesity

Obesity-related complications include type 2 diabetes, hypertension, ventilatory dysfunction, arthrosis, venous and lymphatic circulation diseases, depression, and others. These conditions have a negative impact on health and increase morbidity and mortality.

The Emergence of GLP-1 Receptor Agonists

GLP-1 receptor agonists (GLP1-RAs) have emerged as a promising treatment for obesity. These medications promote satiety, decrease hunger, and ultimately reduce food intake. They also improve glycemic control, induce weight loss, and offer cardio-metabolic and renal protection.

Liraglutide

Liraglutide, a daily injectable GLP-1 RA, has been shown to significantly reduce body weight in both diabetic and non-diabetic individuals. Clinical trials have demonstrated its efficacy in improving glycemic control and reducing cardiovascular risk factors.

Semaglutide

Semaglutide, another GLP-1 RA, has been extensively studied for its weight loss effects. Clinical trials have shown that semaglutide leads to significant and long-lasting weight loss, with improvements in cardiometabolic risk factors.

Tirzepatide

Tirzepatide, a dual agonist of GIP and GLP-1 receptors, has shown superior efficacy in improving glycemic control and inducing weight loss compared to other GLP-1 drugs. It represents a new vista for the treatment of obese individuals.

Lixisenatide and Exenatide

Lixisenatide and exenatide are other GLP-1 RAs that have been evaluated for their efficacy in weight management and glycemic control. These medications have shown significant reductions in body weight and improvements in glycemic control in clinical trials.

Conclusion

GLP-1 agonists have demonstrated significant efficacy in promoting weight loss and improving health outcomes in individuals with obesity, both with and without type 2 diabetes. These medications offer a promising approach to the management of obesity and its associated comorbidities.